JPS63129994A - ヒト由来生理活性物質の製造法 - Google Patents

ヒト由来生理活性物質の製造法

Info

Publication number: JPS63129994A
Authority: JP; Japan
Prior art keywords: cells; cell; human; inducing; substance
Prior art date: 1986-11-21
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

JP27648086A

Other languages

English (en)

Japanese (ja)

Other versions

JPH0348798B2 (2

Inventor

Tadaaki Furuta

古田　忠昭

Tsuneo Sato

恒雄佐藤

Kahori Yoshinari

吉成　河法吏

Mitsuharu Ono

大野　満春

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

National Institute of Advanced Industrial Science and Technology AIST

Original Assignee

Agency of Industrial Science and Technology

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1986-11-21

Filing date

1986-11-21

Publication date

1988-06-02

1986-11-21 Application filed by Agency of Industrial Science and Technology filed Critical Agency of Industrial Science and Technology

1986-11-21 Priority to JP27648086A priority Critical patent/JPS63129994A/ja

1988-06-02 Publication of JPS63129994A publication Critical patent/JPS63129994A/ja

1991-07-25 Publication of JPH0348798B2 publication Critical patent/JPH0348798B2/ja

Status Granted legal-status Critical Current

Links

239000013543 active substance Substances 0.000 title claims abstract description 11
238000004519 manufacturing process Methods 0.000 title claims description 8
230000001939 inductive effect Effects 0.000 claims abstract description 47
230000024245 cell differentiation Effects 0.000 claims abstract description 44
239000000126 substance Substances 0.000 claims abstract description 41
230000004069 differentiation Effects 0.000 claims abstract description 27
208000032839 leukemia Diseases 0.000 claims abstract description 20
238000001962 electrophoresis Methods 0.000 claims abstract description 12
238000002523 gelfiltration Methods 0.000 claims abstract description 7
229920002401 polyacrylamide Polymers 0.000 claims abstract description 6
238000013019 agitation Methods 0.000 claims abstract description 5
210000004027 cell Anatomy 0.000 claims description 101
238000000034 method Methods 0.000 claims description 18
210000002540 macrophage Anatomy 0.000 claims description 7
230000003213 activating effect Effects 0.000 claims description 6
238000001155 isoelectric focusing Methods 0.000 claims description 6
238000012258 culturing Methods 0.000 abstract description 12
230000004913 activation Effects 0.000 abstract 1
230000002779 inactivation Effects 0.000 abstract 1
230000000694 effects Effects 0.000 description 24
239000000411 inducer Substances 0.000 description 21
239000002609 medium Substances 0.000 description 21
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 12
239000000243 solution Substances 0.000 description 11
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
239000000203 mixture Substances 0.000 description 8
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 8
210000002966 serum Anatomy 0.000 description 7
239000001569 carbon dioxide Substances 0.000 description 6
229910002092 carbon dioxide Inorganic materials 0.000 description 6
VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 6
239000008363 phosphate buffer Substances 0.000 description 6
229940088594 vitamin Drugs 0.000 description 6
229930003231 vitamin Natural products 0.000 description 6
235000013343 vitamin Nutrition 0.000 description 6
239000011782 vitamin Substances 0.000 description 6
108090001090 Lectins Proteins 0.000 description 5
102000004856 Lectins Human genes 0.000 description 5
239000004816 latex Substances 0.000 description 5
229920000126 latex Polymers 0.000 description 5
239000002523 lectin Substances 0.000 description 5
206010028980 Neoplasm Diseases 0.000 description 4
229940024606 amino acid Drugs 0.000 description 4
150000001413 amino acids Chemical class 0.000 description 4
239000000872 buffer Substances 0.000 description 4
238000006243 chemical reaction Methods 0.000 description 4
239000003795 chemical substances by application Substances 0.000 description 4
239000011521 glass Substances 0.000 description 4
238000010438 heat treatment Methods 0.000 description 4
210000005104 human peripheral blood lymphocyte Anatomy 0.000 description 4
239000002245 particle Substances 0.000 description 4
210000001539 phagocyte Anatomy 0.000 description 4
239000011780 sodium chloride Substances 0.000 description 4
210000000130 stem cell Anatomy 0.000 description 4
108091003079 Bovine Serum Albumin Proteins 0.000 description 3
108010062580 Concanavalin A Proteins 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
108091005804 Peptidases Proteins 0.000 description 3
102000035195 Peptidases Human genes 0.000 description 3
206010057249 Phagocytosis Diseases 0.000 description 3
239000002202 Polyethylene glycol Substances 0.000 description 3
108010059712 Pronase Proteins 0.000 description 3
108090000631 Trypsin Proteins 0.000 description 3
102000004142 Trypsin Human genes 0.000 description 3
239000002253 acid Substances 0.000 description 3
150000004347 all-trans-retinol derivatives Chemical class 0.000 description 3
201000011510 cancer Diseases 0.000 description 3
239000008157 edible vegetable oil Substances 0.000 description 3
239000012091 fetal bovine serum Substances 0.000 description 3
239000001963 growth medium Substances 0.000 description 3
230000006698 induction Effects 0.000 description 3
238000005259 measurement Methods 0.000 description 3
230000008782 phagocytosis Effects 0.000 description 3
229920001223 polyethylene glycol Polymers 0.000 description 3
230000008569 process Effects 0.000 description 3
230000035755 proliferation Effects 0.000 description 3
239000003760 tallow Substances 0.000 description 3
235000014107 unsaturated dietary fats Nutrition 0.000 description 3
150000003722 vitamin derivatives Chemical class 0.000 description 3
241000894006 Bacteria Species 0.000 description 2
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
101000573199 Homo sapiens Protein PML Proteins 0.000 description 2
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
206010024305 Leukaemia monocytic Diseases 0.000 description 2
208000028018 Lymphocytic leukaemia Diseases 0.000 description 2
WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
VYGQUTWHTHXGQB-FFHKNEKCSA-N Retinol Palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 description 2
208000000389 T-cell leukemia Diseases 0.000 description 2
230000009471 action Effects 0.000 description 2
239000012190 activator Substances 0.000 description 2
SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 2
FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
210000000601 blood cell Anatomy 0.000 description 2
239000001055 blue pigment Substances 0.000 description 2
150000001720 carbohydrates Chemical class 0.000 description 2
239000006285 cell suspension Substances 0.000 description 2
239000003638 chemical reducing agent Substances 0.000 description 2
239000006059 cover glass Substances 0.000 description 2
239000012228 culture supernatant Substances 0.000 description 2
238000010790 dilution Methods 0.000 description 2
239000012895 dilution Substances 0.000 description 2
-1 diterpene compounds Chemical class 0.000 description 2
239000003480 eluent Substances 0.000 description 2
YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 2
238000005194 fractionation Methods 0.000 description 2
230000006870 function Effects 0.000 description 2
239000004220 glutamic acid Substances 0.000 description 2
102000054896 human PML Human genes 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
108010034897 lentil lectin Proteins 0.000 description 2
208000003747 lymphoid leukemia Diseases 0.000 description 2
201000006894 monocytic leukemia Diseases 0.000 description 2
208000025113 myeloid leukemia Diseases 0.000 description 2
230000001766 physiological effect Effects 0.000 description 2
239000002243 precursor Substances 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 2
238000011160 research Methods 0.000 description 2
229930002330 retinoic acid Natural products 0.000 description 2
238000001179 sorption measurement Methods 0.000 description 2
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
239000012085 test solution Substances 0.000 description 2
238000011282 treatment Methods 0.000 description 2
LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
238000005406 washing Methods 0.000 description 2
GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 1
FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
102000013563 Acid Phosphatase Human genes 0.000 description 1
108010051457 Acid Phosphatase Proteins 0.000 description 1
HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
206010000871 Acute monocytic leukaemia Diseases 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
102000009027 Albumins Human genes 0.000 description 1
NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
102100023336 Chymotrypsin-like elastase family member 3B Human genes 0.000 description 1
206010011732 Cyst Diseases 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
102000053187 Glucuronidase Human genes 0.000 description 1
108010060309 Glucuronidase Proteins 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
241001236294 Hebe Species 0.000 description 1
101001056794 Homo sapiens Inosine triphosphate pyrophosphatase Proteins 0.000 description 1
102100025458 Inosine triphosphate pyrophosphatase Human genes 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
102000004877 Insulin Human genes 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
208000035489 Monocytic Acute Leukemia Diseases 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
239000004793 Polystyrene Substances 0.000 description 1
239000012980 RPMI-1640 medium Substances 0.000 description 1
VYGQUTWHTHXGQB-UHFFFAOYSA-N Retinol hexadecanoate Natural products CCCCCCCCCCCCCCCC(=O)OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-UHFFFAOYSA-N 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
229920005654 Sephadex Polymers 0.000 description 1
239000012507 Sephadex™ Substances 0.000 description 1
208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 1
108090000901 Transferrin Proteins 0.000 description 1
102000004338 Transferrin Human genes 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
241000700605 Viruses Species 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
230000001464 adherent effect Effects 0.000 description 1
235000019169 all-trans-retinol Nutrition 0.000 description 1
239000011717 all-trans-retinol Substances 0.000 description 1
210000004102 animal cell Anatomy 0.000 description 1
150000001450 anions Chemical class 0.000 description 1
239000000427 antigen Substances 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
238000003556 assay Methods 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
235000015278 beef Nutrition 0.000 description 1
239000012888 bovine serum Substances 0.000 description 1
235000015115 caffè latte Nutrition 0.000 description 1
239000002775 capsule Substances 0.000 description 1
210000002421 cell wall Anatomy 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
239000003610 charcoal Substances 0.000 description 1
230000021615 conjugation Effects 0.000 description 1
238000011109 contamination Methods 0.000 description 1
208000031513 cyst Diseases 0.000 description 1
230000009849 deactivation Effects 0.000 description 1
230000008260 defense mechanism Effects 0.000 description 1
238000011033 desalting Methods 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
238000007865 diluting Methods 0.000 description 1
229930004069 diterpene Natural products 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
238000000605 extraction Methods 0.000 description 1
235000013305 food Nutrition 0.000 description 1
238000001502 gel electrophoresis Methods 0.000 description 1
229960002885 histidine Drugs 0.000 description 1
230000008105 immune reaction Effects 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
238000004255 ion exchange chromatography Methods 0.000 description 1
238000002955 isolation Methods 0.000 description 1
210000003127 knee Anatomy 0.000 description 1
238000012007 large scale cell culture Methods 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 1
210000003126 m-cell Anatomy 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
239000000463 material Substances 0.000 description 1
238000000691 measurement method Methods 0.000 description 1
229940127554 medical product Drugs 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
HOVAGTYPODGVJG-VEIUFWFVSA-N methyl alpha-D-mannoside Chemical compound CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]1O HOVAGTYPODGVJG-VEIUFWFVSA-N 0.000 description 1
DLEDLHFNQDHEOJ-CSWXFLMBSA-N mezerein Chemical compound O([C@@H]1[C@H]([C@@]23[C@H]4[C@](C(C(C)=C4)=O)(O)[C@H](O)C4(CO)O[C@H]4[C@H]3[C@H]3OC(O2)(O[C@]31C(C)=C)C=1C=CC=CC=1)C)C(=O)\C=C\C=C\C1=CC=CC=C1 DLEDLHFNQDHEOJ-CSWXFLMBSA-N 0.000 description 1
244000005700 microbiome Species 0.000 description 1
125000001446 muramyl group Chemical group N[C@@H](C=O)[C@@H](O[C@@H](C(=O)*)C)[C@H](O)[C@H](O)CO 0.000 description 1
210000003739 neck Anatomy 0.000 description 1
JPXMTWWFLBLUCD-UHFFFAOYSA-N nitro blue tetrazolium(2+) Chemical compound COC1=CC(C=2C=C(OC)C(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC=CC=2)C=2C=CC(=CC=2)[N+]([O-])=O)=CC=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=C([N+]([O-])=O)C=C1 JPXMTWWFLBLUCD-UHFFFAOYSA-N 0.000 description 1
239000003921 oil Substances 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
239000006174 pH buffer Substances 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
150000004633 phorbol derivatives Chemical class 0.000 description 1
239000002644 phorbol ester Substances 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
229920002223 polystyrene Polymers 0.000 description 1
235000015277 pork Nutrition 0.000 description 1
239000001103 potassium chloride Substances 0.000 description 1
235000011164 potassium chloride Nutrition 0.000 description 1
229910000160 potassium phosphate Inorganic materials 0.000 description 1
235000011009 potassium phosphates Nutrition 0.000 description 1
239000000843 powder Substances 0.000 description 1
238000012545 processing Methods 0.000 description 1
108010043524 protease E Proteins 0.000 description 1
238000005086 pumping Methods 0.000 description 1
238000000746 purification Methods 0.000 description 1
230000009467 reduction Effects 0.000 description 1
239000011347 resin Substances 0.000 description 1
229920005989 resin Polymers 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
229960000342 retinol acetate Drugs 0.000 description 1
QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 1
235000019173 retinyl acetate Nutrition 0.000 description 1
239000011770 retinyl acetate Substances 0.000 description 1
229940108325 retinyl palmitate Drugs 0.000 description 1
235000019172 retinyl palmitate Nutrition 0.000 description 1
239000011769 retinyl palmitate Substances 0.000 description 1
238000012552 review Methods 0.000 description 1
238000000926 separation method Methods 0.000 description 1
MFBOGIVSZKQAPD-UHFFFAOYSA-M sodium butyrate Chemical compound [Na+].CCCC([O-])=O MFBOGIVSZKQAPD-UHFFFAOYSA-M 0.000 description 1
239000001488 sodium phosphate Substances 0.000 description 1
229910000162 sodium phosphate Inorganic materials 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
238000003756 stirring Methods 0.000 description 1
229960005322 streptomycin Drugs 0.000 description 1
239000000725 suspension Substances 0.000 description 1
238000012360 testing method Methods 0.000 description 1
WEQHQGJDZLDFID-UHFFFAOYSA-J thorium(iv) chloride Chemical compound Cl[Th](Cl)(Cl)Cl WEQHQGJDZLDFID-UHFFFAOYSA-J 0.000 description 1
231100000027 toxicology Toxicity 0.000 description 1
239000003053 toxin Substances 0.000 description 1
231100000765 toxin Toxicity 0.000 description 1
239000012581 transferrin Substances 0.000 description 1
230000009466 transformation Effects 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
239000012588 trypsin Substances 0.000 description 1
210000004881 tumor cell Anatomy 0.000 description 1
238000000108 ultra-filtration Methods 0.000 description 1

Landscapes

Preparation Of Compounds By Using Micro-Organisms (AREA)
Peptides Or Proteins (AREA)

JP27648086A 1986-11-21 1986-11-21 ヒト由来生理活性物質の製造法 Granted JPS63129994A (ja)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
JP27648086A JPS63129994A (ja)	1986-11-21	1986-11-21	ヒト由来生理活性物質の製造法

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
JP27648086A JPS63129994A (ja)	1986-11-21	1986-11-21	ヒト由来生理活性物質の製造法

Publications (2)

Publication Number	Publication Date
JPS63129994A true JPS63129994A (ja)	1988-06-02
JPH0348798B2 JPH0348798B2 (2)	1991-07-25

Family

ID=17570039

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP27648086A Granted JPS63129994A (ja)	1986-11-21	1986-11-21	ヒト由来生理活性物質の製造法

Country Status (1)

Country	Link
JP (1)	JPS63129994A (2)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS63130600A (ja) *	1986-11-21	1988-06-02	Agency Of Ind Science & Technol	生理活性物質
JPS63129993A (ja) *	1986-11-21	1988-06-02	Agency Of Ind Science & Technol	ヒト由来生理活性物質の製造方法
US5589345A (en) *	1991-02-25	1996-12-31	Institut National De La Sante Et De La Recherche Medicale	Cultures of permanent lines of human promyelocytic cells and their uses for the screening of molecules utilizable in particular in the treatment of leukemias
JP2011033544A (ja) *	2009-08-04	2011-02-17	Hoyu Co Ltd	等電点電気泳動用ゲル及び等電点電気泳動方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS6028934A (ja) *	1983-07-25	1985-02-14	Green Cross Corp:The	細胞分化誘導物質
JPS63130600A (ja) *	1986-11-21	1988-06-02	Agency Of Ind Science & Technol	生理活性物質
JPS63129993A (ja) *	1986-11-21	1988-06-02	Agency Of Ind Science & Technol	ヒト由来生理活性物質の製造方法

1986
- 1986-11-21 JP JP27648086A patent/JPS63129994A/ja active Granted

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS6028934A (ja) *	1983-07-25	1985-02-14	Green Cross Corp:The	細胞分化誘導物質
JPS63130600A (ja) *	1986-11-21	1988-06-02	Agency Of Ind Science & Technol	生理活性物質
JPS63129993A (ja) *	1986-11-21	1988-06-02	Agency Of Ind Science & Technol	ヒト由来生理活性物質の製造方法

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS63130600A (ja) *	1986-11-21	1988-06-02	Agency Of Ind Science & Technol	生理活性物質
JPS63129993A (ja) *	1986-11-21	1988-06-02	Agency Of Ind Science & Technol	ヒト由来生理活性物質の製造方法
US5589345A (en) *	1991-02-25	1996-12-31	Institut National De La Sante Et De La Recherche Medicale	Cultures of permanent lines of human promyelocytic cells and their uses for the screening of molecules utilizable in particular in the treatment of leukemias
JP2011033544A (ja) *	2009-08-04	2011-02-17	Hoyu Co Ltd	等電点電気泳動用ゲル及び等電点電気泳動方法

Also Published As

Publication number	Publication date
JPH0348798B2 (2)	1991-07-25

Legal Events

Date	Code	Title	Description
2006-11-21	EXPY	Cancellation because of completion of term

Publication	Publication Date	Title
US4108849A (en)	1978-08-22	Process for extracting and processing glycoproteins, mucopolysaccharides and accompanying substances
JP3929088B2 (ja)	2007-06-13	骨形成促進及び骨吸収防止剤
EP0704218A2 (en)	1996-04-03	Bone reinforcing agent and foods and drinks product containing the same
KR930002022B1 (ko)	1993-03-22	동결건조 케휘어(kefir) 요구르트의 제조방법
JP2001158736A (ja)	2001-06-12	骨関節疾患の予防及び改善剤
RU2040932C1 (ru)	1995-08-09	Препарат, влияющий на тканевой обмен и применение штамма гриба fusarium sambucinum fuckel var ossicolum (berk.et curf) bilai для его получения
CN117297041B (zh)	2025-07-15	一种可促进胫骨生长的水解蛋黄粉的工业化制备工艺及其应用
JP3018313B2 (ja)	2000-03-13	骨形成促進及び骨吸収防止剤
RU2110182C1 (ru)	1998-05-10	Способ получения биологически активного комплекса для приготовления пищевого или косметического средства
TWI586362B (zh)	2017-06-11	新穎蛋白質素材
JPS63129994A (ja)	1988-06-02	ヒト由来生理活性物質の製造法
CN106729601A (zh)	2017-05-31	胎盘脂多糖、多肽二联免疫增强剂及其制备方法
Babu et al.	1989	Superoxide dismutase activity and blastogenic response of lymphocytes from copper-deficient rats fed diets containing fructose or cornstarch
US4760021A (en)	1988-07-26	Biological response modifier having cell differentiation-induction activity and process for production thereof
Statsenko et al.	2020	New technology for functional dessert production based on soy and pumpkin.
JPH0474360B2 (2)	1992-11-26
JPH0348797B2 (2)	1991-07-25
CN113999884A (zh)	2022-02-01	一种甲鱼生物活性肽的制备方法
CN118667909B (zh)	2024-11-15	虹鳟鱼源多肽提取物及其制备方法与应用
RU2855982C1 (ru)	2026-02-06	Способ получения творожного продукта
CN118903026B (zh)	2025-03-07	一种小牛骨髓水解物脂质体冻干粉及其在促进造血和抗衰老产品中的应用
SU618088A1 (ru)	1978-08-05	Способ получени детского лечебного кисломолочного продукта
JPH0349680A (ja)	1991-03-04	マイクロバクテリウム突然変異株８５１ｒ、及び該株の利用による８５１栄養溶液の製造方法
TWI574696B (zh)	2017-03-21	新穎蛋白質素材
JPH03505200A (ja)	1991-11-14	治療活性のある、特に傷治療または老人医学に用いる作用物質およびかかる作用物質を含む製剤の製造方法

JPS63129994A - ヒト由来生理活性物質の製造法 - Google Patents

Info

Links

Landscapes

Priority Applications (1)

Applications Claiming Priority (1)

Publications (2)

Family

ID=17570039

Family Applications (1)

Country Status (1)

Cited By (4)

Citations (3)

Patent Citations (3)

Cited By (4)

Also Published As

Similar Documents

Legal Events